	Application No.	Applicant(s)	
Notice of Allowability	10/009,945	THOMSEN ET AL.	
	Examiner	Art Unit	
	Hope A. Robinson	1652	
The MAILING DATE of this communication appe All claims being allowable, PROSECUTION ON THE MERITS IS herewith (or previously mailed), a Notice of Allowance (PTOL-85) NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RI of the Office or upon petition by the applicant. See 37 CFR 1.313	(OR REMAINS) CLOSED in this ap or other appropriate communication GHTS. This application is subject to	oplication. If not included n will be mailed in due course. THIS	
1. This communication is responsive to <u>10/30/07</u> .			
2. X The allowed claim(s) is/are 69-72,75,78,81-91,102 and 103	3.	•	
 3. Acknowledgment is made of a claim for foreign priority un a) All b) Some* c) None of the: 1. Certified copies of the priority documents have 2. Certified copies of the priority documents have 3. Copies of the certified copies of the priority documents have International Bureau (PCT Rule 17.2(a)). 	been received. been received in Application No		
* Certified copies not received:			
Applicant has THREE MONTHS FROM THE "MAILING DATE" of noted below. Failure to timely comply will result in ABANDONM THIS THREE-MONTH PERIOD IS NOT EXTENDABLE. 4. A SUBSTITUTE OATH OR DECLARATION must be submi	ENT of this application. tted. Note the attached EXAMINER	R'S AMENDMENT or NOTICE OF	
INFORMAL PATENT APPLICATION (PTO-152) which give	es reason(s) why the oath or declara	ation is deficient.	
5. \square CORRECTED DRAWINGS (as "replacement sheets") mus			
(a) including changes required by the Notice of Draftspers		-948) attached	
1) hereto or 2) to Paper No./Mail Date			
(b) ☐ including changes required by the attached Examiner's Paper No./Mail Date			
Identifying indicia such as the application number (see 37 CFR 1. each sheet. Replacement sheet(s) should be labeled as such in the	84(c)) should be written on the draw ne header according to 37 CFR 1.121	ings in the front (not the back) of (d).	
 DEPOSIT OF and/or INFORMATION about the deposit attached Examiner's comment regarding REQUIREMENT I 	sit of BIOLOGICAL MATERIAL FOR THE DEPOSIT OF BIOLOGIC	must be submitted. Note the CAL MATERIAL.	
	•		
Attachment(s) 1. ☐ Notice of References Cited (PTO-892)	5. Notice of Informal I	Patent Application	
2. Notice of Draftperson's Patent Drawing Review (PTO-948)	_	6. ☐ Interview Summary (PTO-413),	
3. ☐ Information Disclosure Statements (PTO/SB/08),	Paper No./Mail Date 7.		
Paper No./Mail Date 4. Examiner's Comment Regarding Requirement for Deposit	8. 🗌 Examiner's Statem	8. Examiner's Statement of Reasons for Allowance	
of Biological Material	9. Other	9.	
	HOPE ROBINSON PRIMARY EXAMINER	Hope A. Robinson Primary Examiner 17/8/07 Art Unit: 1652	

Amendment to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims:

- 1.-68. (Canceled)
- 69. (Currently amended) A method of screening for a modulator of Smurf activity which comprises detecting modulation of Smurf activity in the presence of a test compound relative to Smurf activity in the absence of the test compound, wherein the Smurf activity detected is the activity of a Smurf comprising a WW domain and a HECT domain, wherein the Smurf has an amino acid sequence similarity of greater than 90% with comprises the amino acid sequence depicted in SEQ ID NO:2, and wherein the Smurf activity is ubiquitination of a Smad polypeptide, ubiquitination of a TGFβ receptor or interaction of a Smurf WW domain with a PPXY domain of a Smad polypeptide.
- 70. (Previously presented) The method according to claim 69, wherein the Smurf activity is ubiquitination of a Smad polypeptide in a host cell.
- 71. (Previously presented) The method according to claim 69, wherein the Smurf activity is interaction of a Smurf WW domain with a PPXY domain of a Smad polypeptide.
- 72. (Previously presented) The method according to claim 71, wherein the test compound is screened for the ability to inhibit the interaction.
 - 73. (Canceled)
 - 74. (Canceled)
- 75. (Previously presented) The method according to claim 69, wherein the Smurf activity detected is the activity of a Smurf comprising the amino acid sequence depicted in SEQ ID NO:2.
 - 76. (Canceled)
 - 77. (Canceled)
- 78. (Previously presented) A method of screening for a modulator of Smurf activity which comprises detecting modulation of Smurf activity in the presence of a test compound relative to Smurf activity in the absence of the test compound, wherein the Smurf activity detected is activity of a human Smurf comprising the amino acid sequence depicted in SEQ ID NO:4, and wherein the Smurf activity is ubiquitination of a Smad polypeptide in a host cell, interaction of a Smurf WW domain with a PPXY domain of a Smad polypeptide, or ubiquitination of a TGFB receptor.

- 79. (Canceled)
- 80. (Canceled)
- 81. (Previously presented) The method according to claim 78, wherein the Smurf activity is ubiquitination of a Smad polypeptide.
- 82. (Previously presented) The method according to claim 78, wherein the Smurf activity is ubiquitination of a Smad polypeptide in a host cell.
- 83. (Previously presented) The method according to claim 78, wherein the Smurf activity is interaction of a Smurf WW domain with a PPXY domain of a Smad polypeptide.
- 84. (Previously presented) The method according to claim 83, wherein the test compound is screened for the ability to inhibit the interaction.
- 85. (Previously presented) The method according to claim 78, wherein the Smurf activity is ubiquitination of a TGFβ receptor.
- 86. (Previously presented) The method according to claim 78, wherein the screening assay is conducted *in vitro*.
- 87. (Previously presented) The method according to claim 78, wherein the screening assay is conducted in a host cell.
- 88. (Previously presented) The method according to claim 69, wherein the Smurf activity is ubiquitination of a Smad polypeptide.
- 89. (Previously presented) The method according to claim 69, wherein the Smurf activity is ubiquitination of a TGFβ receptor.
- 90. (Previously presented) The method according to claim 69, wherein the screening assay is conducted *in vitro*.
- 91. (Previously presented) The method according to claim 69, wherein the screening assay is conducted in a host cell.

92-101 (Canceled)

- 102. (Previously presented) The method according to claim 69, wherein the screening assay is conducted *in vivo*.
- 103. (Previously presented) The method according to claim 78, wherein the screening assay is conducted *in vivo*.

104.-106. (Canceled)